Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing

Hisashi Ishida, Akihiro Iguchi, Michinori Aoe, Takahide Takahashi, Kosuke Tamefusa, Kiichiro Kanamitsu, Kaori Fujiwara, Kana Washio, Takehiro Matsubara, Hirokazu Tsukahara, Masashi Sanada, Akira Shimada

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the cure rate of ALL has greatly improved, a considerable number of patients suffer from relapse of leukemia. Therefore, ALL remains the leading cause of death from cancer during childhood. To improve the cure rate of these patients, precisely detecting patients with high risk of relapse and incorporating new targeted therapies are urgently needed. This study investigated inexpensive, rapid, next-generation sequencing of more than 150 cancer-related genes for matched diagnostic, remission, and relapse samples of 17 patients (3 months to 15 years old) with relapsed ALL. In this analysis, we identified 16 single-nucleotide variants (SNVs) and insertion/deletion variants and 19 copy number variants (CNVs) at diagnosis and 28 SNVs and insertion/deletion variants and 22 CNVs at relapse. With these genetic alterations, we could detect several B cell precursor ALL patients with high-risk gene alterations who were not stratified into the highest-risk group (5/8, 62.5%). We also detected potentially actionable genetic variants in about half of the patients (8/17, 47.1%). Among them, we found that one patient harbored germline TP53 mutation as a secondary finding. This inexpensive, rapid method can be immediately applied as clinical sequencing and could lead to better management of these patients and potential improvement in the survival rate in childhood ALL.

Original languageEnglish
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - Jan 1 2018

Fingerprint

Precursor Cell Lymphoblastic Leukemia-Lymphoma
Genes
Recurrence
Nucleotides
B-Lymphoid Precursor Cells
Germ-Line Mutation
Neoplasm Genes
Cause of Death
Neoplasms
Leukemia
Survival Rate

Keywords

  • ALL
  • Leukemia
  • Molecular genetics
  • Pediatric
  • Precision medicine

ASJC Scopus subject areas

  • Hematology

Cite this

Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing. / Ishida, Hisashi; Iguchi, Akihiro; Aoe, Michinori; Takahashi, Takahide; Tamefusa, Kosuke; Kanamitsu, Kiichiro; Fujiwara, Kaori; Washio, Kana; Matsubara, Takehiro; Tsukahara, Hirokazu; Sanada, Masashi; Shimada, Akira.

In: Annals of Hematology, 01.01.2018.

Research output: Contribution to journalArticle

Ishida, Hisashi ; Iguchi, Akihiro ; Aoe, Michinori ; Takahashi, Takahide ; Tamefusa, Kosuke ; Kanamitsu, Kiichiro ; Fujiwara, Kaori ; Washio, Kana ; Matsubara, Takehiro ; Tsukahara, Hirokazu ; Sanada, Masashi ; Shimada, Akira. / Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing. In: Annals of Hematology. 2018.
@article{7817a25f9681404383f04d834e7f8941,
title = "Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing",
abstract = "Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the cure rate of ALL has greatly improved, a considerable number of patients suffer from relapse of leukemia. Therefore, ALL remains the leading cause of death from cancer during childhood. To improve the cure rate of these patients, precisely detecting patients with high risk of relapse and incorporating new targeted therapies are urgently needed. This study investigated inexpensive, rapid, next-generation sequencing of more than 150 cancer-related genes for matched diagnostic, remission, and relapse samples of 17 patients (3 months to 15 years old) with relapsed ALL. In this analysis, we identified 16 single-nucleotide variants (SNVs) and insertion/deletion variants and 19 copy number variants (CNVs) at diagnosis and 28 SNVs and insertion/deletion variants and 22 CNVs at relapse. With these genetic alterations, we could detect several B cell precursor ALL patients with high-risk gene alterations who were not stratified into the highest-risk group (5/8, 62.5{\%}). We also detected potentially actionable genetic variants in about half of the patients (8/17, 47.1{\%}). Among them, we found that one patient harbored germline TP53 mutation as a secondary finding. This inexpensive, rapid method can be immediately applied as clinical sequencing and could lead to better management of these patients and potential improvement in the survival rate in childhood ALL.",
keywords = "ALL, Leukemia, Molecular genetics, Pediatric, Precision medicine",
author = "Hisashi Ishida and Akihiro Iguchi and Michinori Aoe and Takahide Takahashi and Kosuke Tamefusa and Kiichiro Kanamitsu and Kaori Fujiwara and Kana Washio and Takehiro Matsubara and Hirokazu Tsukahara and Masashi Sanada and Akira Shimada",
year = "2018",
month = "1",
day = "1",
doi = "10.1007/s00277-018-3554-8",
language = "English",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Panel-based next-generation sequencing identifies prognostic and actionable genes in childhood acute lymphoblastic leukemia and is suitable for clinical sequencing

AU - Ishida, Hisashi

AU - Iguchi, Akihiro

AU - Aoe, Michinori

AU - Takahashi, Takahide

AU - Tamefusa, Kosuke

AU - Kanamitsu, Kiichiro

AU - Fujiwara, Kaori

AU - Washio, Kana

AU - Matsubara, Takehiro

AU - Tsukahara, Hirokazu

AU - Sanada, Masashi

AU - Shimada, Akira

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the cure rate of ALL has greatly improved, a considerable number of patients suffer from relapse of leukemia. Therefore, ALL remains the leading cause of death from cancer during childhood. To improve the cure rate of these patients, precisely detecting patients with high risk of relapse and incorporating new targeted therapies are urgently needed. This study investigated inexpensive, rapid, next-generation sequencing of more than 150 cancer-related genes for matched diagnostic, remission, and relapse samples of 17 patients (3 months to 15 years old) with relapsed ALL. In this analysis, we identified 16 single-nucleotide variants (SNVs) and insertion/deletion variants and 19 copy number variants (CNVs) at diagnosis and 28 SNVs and insertion/deletion variants and 22 CNVs at relapse. With these genetic alterations, we could detect several B cell precursor ALL patients with high-risk gene alterations who were not stratified into the highest-risk group (5/8, 62.5%). We also detected potentially actionable genetic variants in about half of the patients (8/17, 47.1%). Among them, we found that one patient harbored germline TP53 mutation as a secondary finding. This inexpensive, rapid method can be immediately applied as clinical sequencing and could lead to better management of these patients and potential improvement in the survival rate in childhood ALL.

AB - Acute lymphoblastic leukemia (ALL) is the most common malignancy in children. Although the cure rate of ALL has greatly improved, a considerable number of patients suffer from relapse of leukemia. Therefore, ALL remains the leading cause of death from cancer during childhood. To improve the cure rate of these patients, precisely detecting patients with high risk of relapse and incorporating new targeted therapies are urgently needed. This study investigated inexpensive, rapid, next-generation sequencing of more than 150 cancer-related genes for matched diagnostic, remission, and relapse samples of 17 patients (3 months to 15 years old) with relapsed ALL. In this analysis, we identified 16 single-nucleotide variants (SNVs) and insertion/deletion variants and 19 copy number variants (CNVs) at diagnosis and 28 SNVs and insertion/deletion variants and 22 CNVs at relapse. With these genetic alterations, we could detect several B cell precursor ALL patients with high-risk gene alterations who were not stratified into the highest-risk group (5/8, 62.5%). We also detected potentially actionable genetic variants in about half of the patients (8/17, 47.1%). Among them, we found that one patient harbored germline TP53 mutation as a secondary finding. This inexpensive, rapid method can be immediately applied as clinical sequencing and could lead to better management of these patients and potential improvement in the survival rate in childhood ALL.

KW - ALL

KW - Leukemia

KW - Molecular genetics

KW - Pediatric

KW - Precision medicine

UR - http://www.scopus.com/inward/record.url?scp=85056647377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85056647377&partnerID=8YFLogxK

U2 - 10.1007/s00277-018-3554-8

DO - 10.1007/s00277-018-3554-8

M3 - Article

C2 - 30446805

AN - SCOPUS:85056647377

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -